Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
3.26 ^USD	+0.93%		+9.03%	-24.71%

06-02	Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)	CI
05-17	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE

Puma Biotechnology Shareholders Rejects Fredric N. Eshelman’s Consent Solicitation

January 08, 2016 at 04:40 pm

On January 8, 2016, Puma Biotechnology, Inc. announced that shareholders representing over 80% of the Company's shares outstanding have rejected the proposals initiated by Fredric Eshelman by revoking consent on the Company's consent revocation card or affirmatively withholding consent on Eshelman's card.

Latest news about Puma Biotechnology, Inc.

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)	06-02	CI
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	05-17	RE
Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	05-02	CI
Puma Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	03-20	MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	03-20	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Transcript : Puma Biotechnology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	02-29	CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	02-29	MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	02-13	CI
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	12-11	CI
Transcript : Puma Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	11-02
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.17, vs. Street Est of $0.14	11-02	MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023	11-02	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting	14/10/23	CI
North American Morning Briefing : Stock Futures Edge Higher as PMI Data Awaited	22/09/23	DJ
Puma Biotechnology Gets FDA Orphan Drug Designation For Alisertib	21/09/23	MT
Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation	21/09/23	DJ
Puma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer Drug	21/09/23	DJ
FDA Clears Puma Biotechnology to Begin Mid-Stage Trial in Small Cell Lung Cancer	08/08/23	MT
Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer	08/08/23	CI

Chart Puma Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Puma Biotechnology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.26 USD

Average target price

4.333 USD

Spread / Average Target

+32.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PUMA BIOTECHNOLOGY, INC.	-24.71%	157M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	38.13B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research